Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy

Genitourinary Cancer

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Eur Urol

de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Bajorin DF, Choueiri TK, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL

doi: 10.1016/j.eururo.2024.07.015

Lymphoma

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial

JAMA Oncol

Daw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, Beishuizen A, Cepelova M, Ceppi F, Fernandez-Teijeiro A, Fosså A, Georgi TW, Hjalgrim LL, Hraskova A, Leblanc T, Mascarin M, Pears J, Landman-Parker J, Prelog T, Klapper W, Ramsay A, Kluge R, Dieckmann K, Pelz T, Vordermark D, Körholz D, Hasenclever D, Mauz-Körholz C

doi: 10.1001/jamaoncol.2024.5636

Lymphoma

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Br J Haematol

Mato S, Carità L, Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I, Celis V, Mendoza C, Guerra-García P, Valero L, Galera A, Tallón M, Pol M, Castrejón-de-Anta N, Frauenfeld L, Garcia N, Campo E, Salaverria I, Verdú-Amorós J

doi: 10.1111/bjh.20012

Multiple Myeloma (MM)

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Eur J Cancer

Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B

doi: 10.1016/j.ejca.2024.115157

Lymphoma

Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis

Leuk Lymphoma

J Wu J, Wade SW, Itani T, Castaigne JG, Kloos I, Peng W, Kanters S, Zoratti MJ, Dreyling M, Shah B, Wang M

doi: 10.1080/10428194.2024.2369653

Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Haematologica

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC

doi: 10.3324/haematol.2024.285977

Lymphoma

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Leuk Lymphoma

Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A

doi: 10.1080/10428194.2024.2371472

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

ASH 2024

Lymphoma

Related content

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma